HERCULES, CA — November 21, 2008 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced today 12 new protocols for electroporation of human primary cells and primary cell lines. The cells include T-cells, neutrophils, and several B-cell lymphomas. The conditions for electroporation were developed using Bio-Rad's Gene Pulser MXcell electroporation system and Gene Pulser electroporation buffer. The protocols can be viewed in Bio-Rad's Transfection Protocol Online Library at https://www.bio-rad.com/genetransferprotocols/.
About Gene Transfer
Gene transfer is a general term used to denote transfection or transformation — the transfer of new genetic material into a cell. Bio-Rad offers several tools for gene transfer including electroporation, lipid-mediated delivery, and particle delivery. Electroporation is a valuable tool for nucleic acid delivery because it can be used for a wide variety of cell types, in particular, primary cells and cells that are difficult to transfect. Lipid-mediated delivery is widely used for mammalian cells. Particle delivery is useful for plant tissues.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.